Back

Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 3 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alberto Foa'

University Hospital of Bologna S. Orsola-Malpighi Polyclinic, Bologna (Italy)

3 More presentations in this session

Presentation thumbnail
Analysis of the PARAGON-HF study results using win ratio
Doctor W. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Feasibility, efficacity and safety of a fast up-titration program of heart failure treatments in real-life practice.
Miss L. Blasi (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Real-world impact of early quadruple therapy in HFrEF: a comparative analysis of sequential vs. simultaneous approaches
Mr D. Ferreira (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Analysis of the PARAGON-HF study results using win ratio
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources